Bide Pharmatech Co. Ltd. A (688073) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Bide Pharmatech Co. Ltd. A ¥36.73, price ¥80.76, upside -54.5%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bide Pharmatech Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
47‑month range ¥27.63 – ¥100.53 · fair‑value band ¥25.74 – ¥45.91 · the ¥80.76 price screens above the ¥36.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Bide Pharmatech Co. Ltd. A in your weekly email
Every Wednesday you see whether Bide Pharmatech Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.
Stock analysis
Bide Pharmatech Co. Ltd. A (688073) currently trades at ¥80.76, while our model-based Fair Value estimate is ¥36.73, implying the stock looks roughly 119.9% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥48.65 per share, and 0 of the 25 models we run sit above the ¥80.76 price.
Bear case: the Growth DCF group reads lowest at ¥11.99, and 25 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥25.74 (bear) to ¥45.91 (bull), the price of ¥80.76 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Bide Pharmatech Co. Ltd. A reported revenue of 1.3B CNY in FY2025 versus 606M CNY in FY2021, a compound +21.6%/yr. Reported net income was 152M CNY in FY2025, compounding +11.7%/yr from FY2021.
Key figures
Market cap 7.3B CNY (≈ $1.1B) · P/E ratio 41.8 · P/S ratio 4.80 · EPS (TTM) ¥1.93 · Dividend yield 1.4% · Net margin 11.5% · Return on equity 8.1% · Return on assets (EBIT) 8.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 81% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −55%, 688073 screens richer than that median.
Fair Value models
Bear ¥25.74Fair Value ¥36.73Bull ¥45.91
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.5633 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+20.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.6%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.1%
Dividend (yield on the price)1.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 18%
Compare Bide Pharmatech Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−52% · Below median
Profitability
Return on equity (TTM)8% · Above median
Return on assets5% · Above median
Net margin (TTM)12% · Above median
Operating margin (TTM)24% · Top 25%
Growth and dividend
Revenue growth9% · Above median
Dividend yield (TTM)1.4% · Below median
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)41.8× · Pricier than median
P/B3.38× · Priciest 25%
P/S (TTM)5.12× · Priciest 25%
P/FCF255.6× · Priciest 25%
EV/EBITDA26.2× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 12
FUTURE (revenue growth)46· sector 21
PAST (return on equity)32· sector 25
HEALTH (low debt)98· sector 96
DIVIDEND (yield)29· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bide Pharmatech Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688073
Frequently asked questions
Is Bide Pharmatech Co. Ltd. A (688073) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥36.73 versus a price of ¥80.76, about −55% upside (overvalued).
What is the fair value of 688073?
Our model-based fair value for Bide Pharmatech Co. Ltd. A is ¥36.73 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥80.76.
What is the quality score of 688073?
Bide Pharmatech Co. Ltd. A has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bide Pharmatech Co. Ltd. A (688073)?
Our model-based price target is the fair value of ¥36.73 (as of Sep 23, 2026) from 25 valuation models. Cautious scenario ¥25.74, optimistic scenario ¥45.91. It is a calculation from audited fundamentals, not an analyst target.
What is the Bide Pharmatech Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥36.73, about −55% upside versus a price of ¥80.76 (overvalued). Cautious scenario ¥25.74, optimistic scenario ¥45.91. The calculation is refreshed regularly with new filings.
What is the revenue of Bide Pharmatech Co. Ltd. A (688073)?
Bide Pharmatech Co. Ltd. A reported trailing-twelve-month revenue of about 1.4B CNY (latest available figure, as of Sep 23, 2026).
Does Bide Pharmatech Co. Ltd. A pay a dividend?
Bide Pharmatech Co. Ltd. A currently shows a dividend yield of about 1.44% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Bide Pharmatech Co. Ltd. A (688073)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bide Pharmatech Co. Ltd. A it is ¥36.73 per share (as of Sep 23, 2026), against a price of ¥80.76. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Bide Pharmatech Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 688073 trades above its calculated fair value: price ¥80.76, fair value ¥36.73, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688073?
No. The price is what the market pays today (¥80.76); the fair value is what the company's own numbers justify (¥36.73). For Bide Pharmatech Co. Ltd. A the two are ¥44.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bide Pharmatech Co. Ltd. A worth?
The market values Bide Pharmatech Co. Ltd. A at about 7.3B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥80.76; our models calculate a fair value of ¥36.73 per share.
What do the bullish and bearish scenarios say about 688073?
Our models span a range for Bide Pharmatech Co. Ltd. A: cautious scenario ¥25.74, base ¥36.73, optimistic ¥45.91 per share (as of Sep 23, 2026, price ¥80.76). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688073?
Bide Pharmatech Co. Ltd. A trades at a price-to-earnings ratio of 41.8 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥36.73 is built from several models across several years. Other multiples: P/B 3.4, P/S 5.1, EV/EBITDA 26.2.
How solid is the balance sheet of Bide Pharmatech Co. Ltd. A (688073)?
Balance-sheet figures for Bide Pharmatech Co. Ltd. A (as of Sep 23, 2026): return on equity 8.1%, debt of 0.04 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 688073 from its 52-week high?
Bide Pharmatech Co. Ltd. A trades at ¥80.76, about 5% below its 52-week high of ¥84.83 and 81% above the low of ¥44.63 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥36.73 is for.
Which stocks are comparable to Bide Pharmatech Co. Ltd. A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bide Pharmatech Co. Ltd. A stock attractive at the current price?
The data as of Sep 23, 2026: price ¥80.76, calculated fair value ¥36.73 (−55%), Quality Score 68/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688073 calculated?
We run Bide Pharmatech Co. Ltd. A through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥36.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Bide Pharmatech Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bide Pharmatech Co. Ltd. A (688073)?
The closing price on Sep 23, 2026 was ¥80.76. Our model-based fair value is ¥36.73, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bide Pharmatech Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥45.91). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Bide Pharmatech Co. Ltd. A
How large is the market capitalisation of Bide Pharmatech Co. Ltd. A (688073)?
The market capitalisation of Bide Pharmatech Co. Ltd. A is 7.3B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bide Pharmatech Co. Ltd. A (688073)?
The price-to-sales ratio of Bide Pharmatech Co. Ltd. A is 4.80 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bide Pharmatech Co. Ltd. A (688073)?
Earnings per share at Bide Pharmatech Co. Ltd. A are ¥1.93 (price ÷ EPS = P/E 41.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bide Pharmatech Co. Ltd. A (688073)?
The dividend yield of Bide Pharmatech Co. Ltd. A is 1.4% (payout 60.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bide Pharmatech Co. Ltd. A (688073)?
The net margin of Bide Pharmatech Co. Ltd. A is 11.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bide Pharmatech Co. Ltd. A (688073)?
The return on equity (ROE) of Bide Pharmatech Co. Ltd. A is 8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bide Pharmatech Co. Ltd. A (688073)?
On an EBIT basis the return on assets of Bide Pharmatech Co. Ltd. A is 8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bide Pharmatech Co. Ltd. A (688073)?
The operating margin of Bide Pharmatech Co. Ltd. A is 23.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bide Pharmatech Co. Ltd. A (688073)?
Revenue at Bide Pharmatech Co. Ltd. A is growing +9.1% versus a year earlier (3y avg +16.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bide Pharmatech Co. Ltd. A (688073)?
Earnings per share at Bide Pharmatech Co. Ltd. A are growing +58.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Bide Pharmatech Co. Ltd. A (688073) generate?
The free cash flow of Bide Pharmatech Co. Ltd. A is 4.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Bide Pharmatech Co. Ltd. A in the live analysis
One click puts Bide Pharmatech Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
